<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Meurin, Philippe</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">POPE-2: No Benefit with Colchicine to Reduce Persistent Postoperative Pericardial Effusion</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-15</style></pages><abstract><style  face="normal" font="default" size="100%">Postoperative pericardial effusion (POPE) is present within the first 7 days after cardiac surgery in 50% to 80% of patients, and the risk for early cardiac tamponade ranges from 0.5% to 1%. There is no drug that can treat this local hemorrhagic complication. The Colchicine Treatment for Post-operative Pericardial Effusion [POPE-2; NCT01266694] was a double-blind, placebo-controlled study to evaluate whether COL could reduce the volume of POPE.</style></abstract><number><style face="normal" font="default" size="100%">27</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>